title: Yet another reason for improving approval and surveillance processes for health technologies.
authors.forename: Francisco M
authors.initials: FM
authors.lastname: Kovacs
authors.forename: Javier
authors.initials: J
authors.lastname: Olabe
authors.forename: Gerard
authors.initials: G
authors.lastname: Urrútia
authors.forename: Javier
authors.initials: J
authors.lastname: Zamora
authors.forename: Joan
authors.initials: J
authors.lastname: Bagó
authors.forename: Luis
authors.initials: L
authors.lastname: Alvarez-Galovich
authors.forename: Víctor
authors.initials: V
authors.lastname: Abraira
mesh_terms: D055396:Bone Morphogenetic Protein 2 / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000139:chemically induced*; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced*; D013123:Spinal Fusion / Q000009:adverse effects* / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000009:adverse effects*
chemical_list: D055396:Bone Morphogenetic Protein 2; D016212:Transforming Growth Factor beta